Skip to main content
. 2017 Sep 6;37(36):8830–8844. doi: 10.1523/JNEUROSCI.0730-17.2017

Figure 7.

Figure 7.

Effects of long-term treatment with perampanel, SNJ-1945, and KPT-350 in GLAST+/−/GLT1-cKO mice. A, Perampanel treatment for 6 weeks delayed motor deficits in the hanging wire test (n = 20 for vehicle-treated and n = 16 for perampanel-treated GLAST+/−/GLT1-cKO mice). B, Percentage survival of vehicle-treated (n = 20) and perampanel-treated (n = 16) GLAST+/−/GLT1-cKO mice calculated using the Kaplan–Meier method (p = 0.076, log rank test). n.s., Not significant. C, ChAT immunofluorescence of the lumbar ventral horn from vehicle-treated and perampanel-treated GLAST+/−/GLT1-cKO mice at 12 weeks of age. D, Quantification of ChAT-positive motor neurons at 12 weeks of age (n = 4 for vehicle-treated and n = 6 for perampanel-treated GLAST+/−/GLT1-cKO mice). E, SNJ-1945 treatment for 6 weeks delayed motor deficits in the hanging wire test (n = 18 for vehicle-treated and n = 16 for SNJ-1945-treated GLAST+/−/GLT1-cKO mice). F, Percentage survival of vehicle-treated (n = 18) and SNJ-1945-treated (n = 16) GLAST+/−/GLT1-cKO mice calculated using the Kaplan–Meier method (p = 0.026, log rank test). *p < 0.05. G, ChAT immunofluorescence of the lumbar ventral horn from vehicle-treated and perampanel-treated GLAST+/−/GLT1-cKO mice at 12 weeks of age. H, Quantification of ChAT-positive motor neurons at 12 weeks of age (n = 4 for vehicle-treated and n = 6 for SNJ-1945-treated GLAST+/−/GLT1-cKO mice). I, Amelioration of motor dysfunction by KPT-350 treatment was observed at 7 weeks of age but not at later (n = 19 for vehicle-treated and n = 14 for KPT-350-treated GLAST+/−/GLT1-cKO mice). J, Percentage survival of vehicle-treated (n = 19) and KPT-350-treated (n = 14) GLAST+/−/GLT1-cKO mice calculated using the Kaplan-Meier method (p = 0.86, logrank test). n.s., Not significant. K, ChAT immunofluorescence of the lumbar ventral horn from vehicle-treated and KPT-350-treated GLAST+/−/GLT1-cKO mice at 12 weeks of age. L, Quantification of ChAT-positive motor neurons at 12 weeks of age (n = 4 for vehicle-treated and n = 6 for KPT-350-treated GLAST+/−/GLT1-cKO mice). Scale bars: C, G, K, 100 μm. A, E, I, *p < 0.05, **p < 0.01, ***p < 0.001 (post hoc unpaired two-tailed t test at corresponding time point after two-way repeated-measures ANOVA). D, H, L, *p < 0.05. n.s., Not significant (unpaired two-tailed t test). Red broken lines represent the first day of administration. All data are expressed as the mean ± SEM.